Tolerability and pharmacokinetics of remoxipride after intramuscular administration.
A study was undertaken in seven schizophrenic patients to evaluate the tolerability and examine the pharmacokinetics of intramuscularly administered remoxipride after a single 200 mg dose and at steady state following repeated doses of 200 mg twice daily for one week. Comparisons of AUC, t1/2 and tmax using the Wilcoxon's signed rank test showed no significant difference between single dose and steady state indicating that the pharmacokinetics of intramuscular remoxipride were linear. The steady-state Cmax was found to be significantly larger than that after single dose and the increase was accounted for by the predicted accumulation factor, assuming linear kinetics. Although the inter-individual variability in plasma concentrations was large, the intra-individual variability was low as shown by the reproducibility of the single-dose and steady-state plasma curves. Remoxipride, administered intramuscularly, was well tolerated.
Kahn
J P
JP
Centre Hospitalier Regional de Nancy, Psychologie Medicale et Psychotherapie Hôpital Jeanne D'Arc, Toul, France.
Yisak
W
W
Albaret
C
C
Nilsson
L
L
Zaar-Hedin
A
A
Laxenaire
M
M
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017330:Remoxipride; D012559:Schizophrenia / Q000097:blood*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D001549:Benzamides; D017330:Remoxipride